

1 **Super-infections and relapses occur in chronic norovirus infections**

2 Julianne R Brown¹, Sunando Roy², Helena Tutill², Rachel Williams², Judith Breuer^{1,2}

3

4 1 Microbiology, Virology and Infection Prevention and Control, Great Ormond Street Hospital for
5 Children NHS Foundation Trust

6 2 Infection and Immunity, University College London, UK

7

8 Running title: Norovirus super-infections

9 Abstract word count: 241

10 Text word count: 1317

11 **Corresponding author**

12 Julianne R Brown

13 Julianne.brown@nhs.net

14 0044 20 7405 9200 Ext 5929

15

16 **Abstract**

17 **Background**

18 Norovirus causes chronic infections in immunocompromised patients with considerable associated
19 morbidity. It is not known whether chronic infections involve super- or re-infections or relapses.

20 **Objectives**

21 To retrospectively investigate whether longitudinal sampling in chronically infected patients
22 demonstrates persistent infection with the same virus, or super- or re-infection.

23 **Study design**

24 Norovirus full genomes were generated from 86 longitudinal samples from 25 paediatric patients.
25 Consensus sequences were used for phylogenetic analysis and genotyping.

26 **Results**

27 Super-infections occurred in 17% of chronically infected patients who were continuously PCR
28 positive; including two with mixed norovirus infections. The median duration of infection was 107
29 days longer in those with super-infections; however this was not statistically significant. A third of
30 patients with interrupted norovirus shedding continued to be infected with the same virus despite
31 up to 2 months of PCR negative stools, classified as a relapse. The majority (67%) of patients with
32 interrupted shedding were re-infected with a different genotype.

33 **Conclusions**

34 Chronically infected patients who are continuously PCR positive are most likely to remain infected
35 with the same virus; however super-infections do occur leading to mixed infection. Patients with
36 interrupted shedding are likely to represent re-infection with a different genotype, however
37 relapsing infections also occur.

38 Our findings have implications for infection control as immunosuppressed patients remain
39 susceptible to new norovirus infections despite current or recent infection and may continue to be
40 infectious after norovirus is undetectable in stool. The relevance to children without co-morbidities
41 remains to be determined.

42 **Highlights**

- 43 • Super-infections occur in 17% of continuously shedding chronic norovirus infections
- 44 • Re-infections occur in two-thirds of chronic infections with interrupted shedding
- 45 • Relapses occur in a third of chronic infections with interrupted shedding
- 46 • Patients are susceptible to super- and re-infection with different genotypes

47 **Keywords**

48 Norovirus; chronic; re-infection; super-infection; relapse; full genomes

49 **Background**

50 Norovirus is a leading cause of gastroenteritis. Infections are typically self-limiting in
51 immunocompetent hosts, with limited morbidity aside from dehydration. In immunocompromised
52 patients however, there is a risk of chronic infection with significant associated morbidity [1].
53 Chronic infections are bi-phasic with an acute phase of vomiting and diarrhoea, followed by chronic
54 viral shedding and diarrhoea lasting weeks to years. The majority of case reports describe patients to
55 be symptomatic during this extended period of shedding, with up to 24 bowel movements per day
56 [2]. However chronic infections can experience intermittent symptoms of diarrhoea [3] or be
57 asymptomatic [4].

58 The *Norovirus* genus is comprised of five genogroups (GI–GV), of which GI, GII and, to a limited
59 extent, GIV cause infections in humans. Each genogroup is further classified into genotypes; GI.1–9
60 and GII.1–22. GII.4 genotypes, which are the predominant global genotype since the mid-1990s [5],
61 are divided into variant types. Norovirus has a dual typing system based on the polymerase (ORF1)
62 and capsid (ORF2) sequences.

63 **Objectives**

64 We retrospectively sequence full norovirus genomes from longitudinally sampled chronic infections
65 for genotyping and phylogenetic analysis, to determine whether patients remain persistently
66 infected with the same strain or whether super- or re-infections occur.

67 **Study Design**

68 Eighty-six longitudinal stool samples were retrospectively sequenced from 25 paediatric patients,
69 with two to eight samples per patient. Samples were collected between November 2012 and
70 January 2016 from patients with persistent norovirus infections (PCR positive >1 month) for whom
71 two or more longitudinal stool specimens were available. Patients were under the care of a UK
72 paediatric tertiary referral hospital. Norovirus positive patients were tested weekly whilst inpatients
73 or monthly whilst outpatients for the presence or absence of norovirus by the diagnostic Virology

74 laboratory using a reverse-transcriptase real-time multiplex PCR to detect norovirus GI and GII, the
75 methods for which are described elsewhere [6].

76 Of the 25 patients, 18 were continuously norovirus positive (continuous shedding), with a median of
77 129 days between the first and last sequenced sample (range 7–466). A further seven patients had a
78 period between the first and last sequenced sample during which norovirus was not detected in
79 stool, before once again being detected (interrupted shedding). In addition two of the 18 patients
80 who shed norovirus continuously (Patient 63 and 73), proceeded to become norovirus PCR negative
81 following which both became positive again. In total nine patients had interrupted norovirus
82 shedding (median 153 days undetected, range 9–466).

83 Norovirus genome sequencing and phylogenetic analysis are described in Supplementary Methods.

84 **Results**

85 *Continuously positive patients*

86 Of the 18 patients who were continuously norovirus PCR positive, 15/18 (83%) remained infected
87 with the same genotype throughout the study period, classified as persistent infections (Table 1).
88 The longitudinal samples from each of these patients cluster together on the phylogenetic tree
89 (Figure 1), indicating these patients remained infected not only with the same genotype but with the
90 same virus.

91 Three of the 18 (17%) patients with continuous shedding had evidence of infection with a second
92 genotype occurring during the study period (Patients 73, 65 and 101), classified as super-infections.
93 Super-infection is proven for two patients (Patient 65 and Patient 101) in whom co-infection with
94 two different genotypes was detected in a single sample. Patient 73 was initially infected with a
95 GII.Pe_GII.4 virus then became infected with GII.P16_GII.17, although a mixture of the two
96 genotypes in the same sample was not detected. Patient 73 was continually positive for norovirus in
97 stool; the interval between detection of GII.Pe_GII.4 and of GII.P16_GII.17 was 22 days with an

98 additional positive stool sample taken during this interval (not available for sequencing). We cannot
99 confirm whether Patient 73 cleared GII.Pe_GII.4 prior to infection with GII.P16_GII.17 or whether a
100 temporary mixed infection occurred, however given the short interval between positive PCR tests
101 (1–2 weeks), the latter is most probable.

102 These data suggest that in patients who are continuously norovirus PCR positive, super-infection
103 occurs in a sixth (17%) of cases. The median duration of infection was 322 days (range 58–738 days)
104 in the three patients who had a super-infection and 215 days (range 14–711 days) in the 15 who did
105 not. The duration of infection was not significantly different ($P = 0.360$).

106 *Patients with interrupted norovirus shedding*

107 Of the nine patients who become norovirus PCR negative and then positive again, five (Patients 34,
108 68, 73, 147 and 176) acquired a second virus with a different genotype to the first, classified as re-
109 infection (Table 1). For Patient 73 this was the second incidence of re-infection, the first having
110 occurred whilst continuously norovirus PCR positive (Supplementary Figure 1).

111 Another of the nine patients, Patient 63, appeared to be infected with the same genotype
112 (GII.P21_GII.3) after a period of 466 days during which norovirus was undetectable by PCR.

113 Phylogenetic analysis revealed the second virus to be a different variant of GII.P21_GII.3, since the
114 sequences from before and after the PCR negative period do not cluster together (Figure 1).

115 Thus the majority (6/9, 67%) of patients with interrupted norovirus shedding had been re-infected
116 with a different genotype or variant.

117 For the remaining three patients (Patients 31, 72 and 75), the second virus was of the same
118 genotype, clustering with the earlier virus in the phylogenetic analysis tree (Figure 1), classified as
119 relapse. This suggests cryptogenic persistence of the first virus. The three relapse patients had the
120 shortest intervals during which norovirus was undetectable; less than two months compared to 2–15
121 months for those who were re-infected with a new genotype or variant.

122 *Single Nucleotide Variants in longitudinal samples*

123 Excluding those patients with mixed infections, in the patients who were continually infected with
124 the same virus there was a strong positive correlation between the number of consensus sequence
125 pairwise single nucleotide variants (SNVs) and the number of days separating specimen collection (R^2
126 0.775, $P < 0.001$) (Supplementary Figure 2) with up to 131 SNVs accumulating across the genome
127 over 445 days.

128 **Discussion**

129 We use full genome sequencing to show that super-infection and re-infection occurs in patients in
130 whom norovirus can be detected over long periods. When the virus is shed continuously, super-
131 infection was detected in a sixth (17%) of patients while re-infections accounted for the majority
132 (67%) of cases where norovirus was detected after interrupted shedding. Whether a lack of
133 protection against super- and re-infection extends to children without comorbidities remains to be
134 determined.

135 Conversely, relapse was identified in patients in whom norovirus shedding was interrupted for up to
136 two months. These data may have implications for clinical practice; chronically infected patients
137 who appear to clear norovirus may still harbour persistent but undetectable virus. Whether or not
138 these patients present a transmission risk is not known. However, a prudent course of action would
139 be to consider immunosuppressed patients who have cleared virus after a chronic infection as
140 potentially infectious for up to 2-3 months following the last positive stool and to continue PCR
141 surveillance for this period. Given the small sample size in this study (three patients relapsing) a
142 larger study is required to confirm these findings.

143 Our data confirms previous observations that viruses persistently infecting immunocompromised
144 patients are continuously mutating, leading to the accumulation of SNVs [3, 7]. The resulting intra-
145 host population can be observed as a heterogeneous quasispecies which some have suggested may

146 be a reservoir for the emergence of novel viral variants [7, 8], however the estimated rarity of such
147 events has led to the conclusion that immunosuppressed hosts are not the principle source of novel
148 variants at the epidemiological scale [9].

149 Mixtures of norovirus strains have been detected in individuals in oyster-borne norovirus outbreaks
150 [10, 11]; to our knowledge this is the first identification of mixed genotypes within a single host in
151 sporadic infections. Co-infecting norovirus strains within an individual provides the opportunity for
152 viral recombination to occur, a feature that is known to be important in norovirus evolution and has
153 been suggested to contribute to the emergence of new pandemic strains [12].

Figure titles

Table 1. Summary of longitudinally sampled norovirus infections. The occurrence of re-infection is inferred from phylogenetic analysis of norovirus full genome sequences

Figure 1. Full genome maximum likelihood phylogeny of longitudinal norovirus sequences. Sequences are labelled with a unique patient number (Px, NORO/XX) and serial longitudinal numbering (e.g. NORO/XX-1). The node shape and colour indicates whether the position on the tree suggests persistence of the same virus, re-infection with a different genotype or re-infection with a different strain of the same genotype. Co-infections with multiple genotypes (Patient 65 and 101) are not shown since reliable consensus sequences for phylogenetic analysis cannot be generated.

Footnote: Longitudinal samples from Patients 58 and 63 (63-1 and 63-2) do not cluster as closely together as longitudinal samples from other patients; 445 and 135 days had passed between the longitudinal samples therefore is consistent with accumulation of mutations over time. The second sample from patient 58 clusters closely with samples from patient 68 and the early samples from Patient 63 cluster with samples from Patient 61; these patients were epidemiologically linked (data not shown).

Supplementary Figure 1. Timeline of norovirus detection in Patient 73. Orange markers indicate detection of norovirus GII.Pe_GII.4, blue detection of GII.P16_GII.17 and green detection of GII.P21_GII.3. Grey markers indicate norovirus positive samples that were not available for sequencing. Black markers with a Ct value of zero indicate norovirus was not detected by RT-qPCR.

Supplementary Figure 2. Number of intra-host pairwise single nucleotide variants (SNVs) across norovirus full genomes in longitudinally sampled norovirus infections, plotted against number of days separating the samples.

Conflict of interest statement

The authors declare no conflict of interest. The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Funding statement

This work was supported by the PATHSEEK European Union's Seventh Programme for research, technological development and demonstration (grant number 304875) and a National Institute for Health Research (NIHR) doctoral fellowship (grant number NIHR-HCS-D12-03-15) to JRB. JBreuer receives funding from the NIHR UCL/UCLH biomedical research centre (BRC).

Acknowledgments

We acknowledge the infrastructure support from the UCL Pathogen Genomics Unit (PGU), the NIHR UCL/UCLH BRC, the UCL MRC CMMV and the Great Ormond Street Hospital for Children NHS Foundation Trust Microbiology, Virology and Infection Prevention and Control department. All research at Great Ormond Street Hospital NHS Foundation Trust is made possible by the NIHR Great Ormond Street Hospital Biomedical Research Centre. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.

References

- [1] Green KY. Norovirus infection in immunocompromised hosts. *Clin Microbiol Infect.* 2014;20:717-23.
- [2] Ghosh N, Malik FA, Daver RG, Vanichanan J, Okhuysen PC. Viral associated diarrhea in immunocompromised and cancer patients at a large comprehensive cancer center: a 10-year retrospective study. *Infectious diseases (London, England).* 2016:1-7.
- [3] Schorn R, Hohne M, Meerbach A, Bossart W, Wuthrich RP, Schreier E, et al. Chronic norovirus infection after kidney transplantation: molecular evidence for immune-driven viral evolution. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.* 2010;51:307-14.
- [4] Westhoff TH, Vergoulidou M, Loddenkemper C, Schwartz S, Hofmann J, Schneider T, et al. Chronic norovirus infection in renal transplant recipients. *Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.* 2009;24:1051-3.
- [5] Vinje J. Advances in Laboratory Methods for Detection and Typing of Norovirus. *Journal of clinical microbiology.* 2014.

- [6] Brown JR, Shah D, Breuer J. Viral gastrointestinal infections and norovirus genotypes in a paediatric UK hospital, 2014-2015. *Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology*. 2016;84:1-6.
- [7] Bull RA, Eden JS, Luciani F, McElroy K, Rawlinson WD, White PA. Contribution of intra- and interhost dynamics to norovirus evolution. *Journal of virology*. 2012;86:3219-29.
- [8] Sukhrie FH, Siebenga JJ, Beersma MF, Koopmans M. Chronic shedders as reservoir for nosocomial transmission of norovirus. *Journal of clinical microbiology*. 2010;48:4303-5.
- [9] Eden JS, Chisholm RH, Bull RA, White PA, Holmes EC, Tanaka MM. Persistent infections in immunocompromised hosts are rarely sources of new pathogen variants. *Virus evolution*. 2017;3:vex018.
- [10] Wang Y, Zhang J, Shen Z. The impact of calicivirus mixed infection in an oyster-associated outbreak during a food festival. *Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology*. 2015;73:55-63.
- [11] Symes SJ, Gunsekere IC, Marshall JA, Wright PJ. Norovirus mixed infection in an oyster-associated outbreak: an opportunity for recombination. *Archives of virology*. 2007;152:1075-86.
- [12] Eden JS, Tanaka MM, Boni MF, Rawlinson WD, White PA. Recombination within the pandemic norovirus GII.4 lineage. *Journal of virology*. 2013;87:6270-82.